Traditionally, it has been used for more than 2500 years in both Ayurvedic and Chinese medicine, with growing interest in its effects in metabolic and cardiovascular disease in the Western world in the last decade. Berberine has a wide range of healthful uses that include cardiovascular, anti-inflammatory, and antimicrobial (it acts against bacterial diarrhea, intestinal parasites, fungal infections, In the first study, 36 adults with newly diagnosed type 2 diabetes were randomly assigned to treatment with berberine or metformin (500 mg 3 times/day) in a 3-month trial. The hypoglycemic effect of berberine was similar to that of metformin. Metformin is a widely used first-line antidiabetic drug prescribed by doctors for the treatment of type 2 diabetes, particularly in the overweight and obese, and those with normal kidney function. Significant changes were observed in the berberine group: * Advanced glycation end-products (AGEs) result from a chain of chemical reactions after an initial glycation reaction. The intermediate products are known, variously, as Amadori, Schiff base, and Maillard products (named after the researchers who first described them). Side products generated in intermediate steps may be oxidizing agents (such as hydrogen peroxide), or not (such as beta amyloid proteins). The UK Prospective Diabetes Study, a large clinical trial performed in 1980-90s, provided evidence that metformin reduced the rate of adverse cardiovascular outcomes in overweight patients with type 2 diabetes relative to other antihyperglycemic agents. Treatment guidelines for major professional associations including the European Association for the Study of Diabetes, the European Society for Cardiology and the American Diabetes Association, now describe evidence for the cardiovascular benefits of metformin as equivocal. In 2017, the American College of Physicians's guidelines were updated to recognize metformin as the first-line treatment for type-2 diabetes. For example, a 2014 review found tentative evidence that people treated with sulfonylureas had a higher risk of severe low blood sugar events (RR 5.64), though their risk of non-fatal cardiovascular events was lower than the risk of those treated with metformin (RR 0.67). There was not enough data available at that time to determine the relative risk of death or of death from heart disease. study known as the Diabetes Prevention Program, participants were divided into groups and given either placebo, metformin, or lifestyle intervention and followed for an average of three years. Metformin treatment of people at a prediabetes stage of risk for type 2 diabetes may decrease their chances of developing the disease, although intensive physical exercise and dieting work significantly better for this purpose. The intensive program of lifestyle modifications included a 16-lesson training on dieting and exercise followed by monthly individualized sessions with the goals of decreasing weight by 7% and engaging in physical activity for at least 150 minutes per week. The incidence of diabetes was 58% lower in the lifestyle group and 31% lower in individuals given metformin. Among younger people with a higher body mass index, lifestyle modification was no more effective than metformin, and for older individuals with a lower body mass index, metformin was no better than placebo in preventing diabetes.
The fear of lactic acidosis happening was based on a study from the 1940s in a massively compromised patient cohort. These patients were in end-stage renal failure and also obese and diabetic. We must be mindful that correlation does not equate to causation. While metformin has been contraindicated in moderate and severe renal impairment, the reported incidence of lactic acidosis in clinical practice has proved to be very low (fewer than 10 cases per 100,000 patients). The studies on metformin and cardiovascular risk were also performed on a thoroughly compromised patient population group of morbidly obese diabetics who were using anywhere from 6-9 grams of metformin per day – three to five times the recommended and commonly used dose. Other studies show it’s actually the opposite: that metformin may actually reverse mitochondrial dysfunction! There have also been studies out of Taiwan showing that metformin taken by diabetics for long periods of time (12 years or longer) can nearly double the risk of Alzheimer’s and Parkinson’s, but – similar to the studies on lactic acidosis – this study involved heavy use for extended periods of time. The information in this monograph is intended for informational purposes only, and is meant to help users better understand health concerns. Information is based on review of scientific research data, historical practice patterns, and clinical experience. This information should not be interpreted as specific medical advice. Users should consult with a qualified healthcare provider for specific questions regarding therapies, diagnosis and/or health conditions, prior to making therapeutic decisions.
Actually metformin is a safe enough drug to take. It doesnt stimulate the pancreas to go into overdrive. I am not sure about cinnamon, works for some not for others. Aug 1, 2017. The Dark Side Of Metformin A "Longevity Wonder Drug" That Promises to. Exit Metformin Enter A Natural Dietary Approach To Blood Sugar.